Clee Medical Secures Seed Financing to Advance Real-Time Brain Imaging for Neurosurgery

Clee Medical, a Swiss neurotechnology startup developing novel ultra-high-resolution real-time imaging for brain surgery, led by Matthew Lapinski, Abed Hammoud, Jules Scholler, and Gary Evans, has announced the successful closing of its seed financing round led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick, with continued participation from their existing partner and investor, Wyss Geneva.

The financing will enable Clee Medical to accelerate development and clinical validation of its Neuro Access platform, a minimally invasive technology designed to give neurosurgeons real-time visualization of brain anatomy and critical structures during stereotactic procedures.

“Neurosurgery still relies heavily on pre-operative imaging, while the reality in the operating room is dynamic and uncertain,” said Matthew Lapinski, Co-Founder and CEO of Clee Medical. “This Seed round enables us to introduce real-time visibility into the brain, supporting safer procedures and expanding the potential of minimally invasive neurosurgery.”

Improving Surgical Precision

Neurosurgical procedures demand millimeter-level accuracy, yet anatomical shifts and limited visibility during surgery make targeting difficult.

Clee Medical’s Neuro Access platform addresses this challenge with real-time, ultra-high-resolution imaging from within the brain, helping surgeons navigate complex anatomy with greater confidence. The technology is being developed for applications including functional neurosurgery and neuro-oncology.

Advancing Toward Clinical Milestones

The Seed financing will expand development and clinical programs, supporting progress toward a first-in-human study and early clinical adoption.

“Clee Medical is addressing a critical unmet need in neurosurgery: real-time visualization during minimally invasive procedures,” said Tilmann Petersen, Investment Manager at HTGF, noting the team’s track record developing market-standard systems like the Stealth Station and their potential to build a category-defining neurotechnology platform.

A Milestone for Swiss Neurotechnology

The Seed round marks Clee Medical’s move from preclinical development to clinical translation, positioning Neuro Access for real-world use with backing from a strong European investor syndicate and Wyss Geneva.

Led by co-founders Matt Lapinski and Abed Hammoud, the team combines deep experience in Class III medical devices and market-leading neurosurgical systems, with a vision to equip surgeons with real-time insight that improves safety and outcomes in complex brain procedures.